Kenmotsu H, Wakuda K, Mori K, Kato T, et al. Randomized phase II study of osimertinib plus bevacizumab versus osimertinib for untreated patients with non-squamous non-small cell lung cancer harboring EGFR mutations; WJOG9717L study. J Thorac Oncol 2022 May 27. pii: S1556-0864(22)00265.
PMID: 35636696